These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
304 related items for PubMed ID: 28734620
21. Validation of a focused echocardiographic training program in first opinion practice. Dickson D, Harris J, Chang CH, Patteson M, Hezzell MJ. J Vet Intern Med; 2022 Nov; 36(6):1913-1920. PubMed ID: 36221315 [Abstract] [Full Text] [Related]
23. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease. Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, Ward JL. J Vet Intern Med; 2024 Nov; 38(1):51-60. PubMed ID: 37909399 [Abstract] [Full Text] [Related]
24. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, Baduel L. J Vet Intern Med; 2013 Nov; 27(5):1083-91. PubMed ID: 23869534 [Abstract] [Full Text] [Related]
29. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not? Kim HJ, Kim J, Kim S, Kim HJ. BMC Vet Res; 2023 Mar 07; 19(1):59. PubMed ID: 36882760 [Abstract] [Full Text] [Related]
33. Tricuspid annular plane systolic excursion in dogs with myxomatous mitral valve disease with and without pulmonary hypertension. Poser H, Berlanda M, Monacolli M, Contiero B, Coltro A, Guglielmini C. J Vet Cardiol; 2017 Jun 07; 19(3):228-239. PubMed ID: 28579307 [Abstract] [Full Text] [Related]
35. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs. Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M. J Vet Intern Med; 2017 Mar 07; 31(2):316-325. PubMed ID: 28145607 [Abstract] [Full Text] [Related]
37. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics. Franchini A, Borgarelli M, Abbott JA, Menciotti G, Crosara S, Häggström J, Lahmers S, Rosenthal S, Tyrrell W. J Vet Cardiol; 2022 Jun 07; 41():99-120. PubMed ID: 35316716 [Abstract] [Full Text] [Related]
38. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease. Yata M, Kooistra HS, Beijerink NJ. J Vet Intern Med; 2019 Mar 07; 33(2):462-470. PubMed ID: 30703246 [Abstract] [Full Text] [Related]
39. Correlation between serum homocysteine concentration and severity of mitral valve disease in dogs. Lee CM, Jeong DM, Kang MH, Kim SG, Han JI, Park HM. Am J Vet Res; 2017 Apr 07; 78(4):440-446. PubMed ID: 28345991 [Abstract] [Full Text] [Related]
40. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease. Caivano D, Rishniw M, Birettoni F, Patata V, Giorgi ME, Porciello F. J Vet Cardiol; 2018 Apr 07; 20(2):102-114. PubMed ID: 29459124 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]